Introduction
Since the advent of AIDS, equality and non-discrimination in access to prevention and treatment have been major issues, because so high a percentage of patients belongs to stigmatised or disadvantaged groups, such as drug users, ethnic minorities, immigrants or women. Disadvantaged groups have been shown to have less access to zidovudine treatment [1] and pneumocystis carinii pneumonia (PCP) prophylaxis [2] ; they also start HAART later [3] . Aside from the barriers to health care due to patients' financial situation and educational level, physicians' anticipation that patient compliance will be poor [4, 5] has been shown to explain delayed initiation of HAART. Moreover, several US studies, conducted mainly before the advent of HAART, identified physician experience as a determinant of progression to AIDS and survival [6, 7, 8, 9 ,10].
Since a very high level of adherence is required to fully benefit from HAART, a multidisciplinary approach to HIV care is need to support patients and help them deal with the practical, social and emotional dimensions of living with HIV [11, 12] .
Hospitals and health care centres should provide comprehensive HIV care with a range of medical and social services to achieve the best possible outcomes. Rapid progress in clinical research necessitates the regular updating of treatment recommendations.
Physicians should update their practice regarding treatment so that all patients can benefit from the most recent scientific advances. Such rapid changes might vary according to physician characteristics, type of setting and size of HIV caseload.
The purpose of this paper is to describe the heterogeneity of the hospital HIV treatment provided in France and its effect on treatment outcome.
Material and methods

Study design
This analysis used data from the 2003 ANRS-EN12-VESPA study, a large nationally representative two-stage cross-sectional survey, aimed at studying the social situation of HIV-infected persons in France. The study design has been detailed elsewhere [13] . 85 hospitals providing HIV care were randomly selected among the 143 French hospitals with a HIV caseload greater than 60 patients, stratifying on geographic location and size of HIV caseload. As some large hospitals had several departments serving patients with HIV, the 85 hospitals were composed of 102 departments providing HIV care. Doctors in each of these departments randomly recruited a sample of outpatients (representing about 5% of their caseload) among those with the following eligibility criteria: having been diagnosed with HIV-1 infection for at least 6 months, aged 18 or older, and, if not a French citizen, having lived in France for at least 6 months. Patients who understood French very poorly were excluded. The study design and informed consent procedures complied with the ethical and statutory requirements of the French Data Protection Authority (Commission Nationale Informatique et Libertés).
Information collected
Information was collected for each hospital department and for each individual patient.
In each department, a clinical research assistant completed an information sheet on the current HIV patient caseload, department capacity (number of physicians, of inpatient beds, of day hospital beds, and of weekly outpatient appointments), participation in 
Variables of interest
The heterogeneity of the departments delivering HIV care was studied for adherence and various measures of treatment outcome.
Adherence to HAART was assessed with a dichotomous outcome (high versus moderate or poor adherence) validated in previous cohort studies [14, 15] . First, participants were asked about their compliance with HAART in the prior 7 days. They had to choose among the following items, each corresponding to a level of adherence: 'I inserm-00431832, version 1 -13 Nov 2009 have followed scrupulously my treatment' (=high adherence), 'I have followed my treatment despite some small lapses' (=moderate adherence), 'I have frequently modified doses or time schedule', 'I have almost never complied with prescription instructions', 'I have stopped treatment' (=poor adherence). Then, participants were asked whether or not they had missed at least one dose during the previous week-end, whether they had taken the whole daily dose in only one take in the previous 7 days, or whether they had failed to respect the time schedule for at least one dose during the same period. Participants previously ranked as highly adherents but who had answered 'yes' to one of these three questions were reallocated to the 'moderate adherence' category.
Treatment outcome was assessed using four different indicators, three defining failure and one denoting success:
• Immunological response was defined as the absence of an increase of ≥100 CD4 cells/mm 3 between HAART initiation and data collection. This threshold was chosen on the basis of the review by May and colleagues [16] , showing a median 100 cells increase in CD4 cell count in the first 6 month on HAART, which was here the minimum duration.
• Virological failure was defined as having detectable HIV-RNA (<400 copies/ml) at data collection;
• Immunovirological failure was defined as the combination of a CD4 cell count ≤200/mm 3 and detectable HIV-RNA at data collection;
• Lastly, immunovirological success was defined as the combination of a CD4 cell count ≥ 500/mm 3 and undetectable HIV-RNA at data collection. [17] inserm-00431832, version 1 -13 Nov 2009
Population of interest
The VESPA study included 2932 participants from 102 different departments. For the present analysis, we included only the 699 participants (of 97 different departments)
who had been diagnosed in 1996 or later and had received HAART for at least 6 months at the time of the study. The medical history of patients diagnosed before and after the HAART era is indeed too different to be pooled in an analysis on this topic.
Furthermore, the much higher mortality before 1996 indicates much greater selection bias among the patients diagnosed before that year. A minimum of 6 months is assumed necessary before the treatment can be judged effective and thus classified as a success or failure.
Statistical methods
For each of the five outcomes, the existence of a centre effect was assessed by testing the department as a random variable in a binary mixed model, without any other covariate. If this random variable appeared to be significant, the next step of the analysis was to include in the models covariates measured at the individual level (age, sex, sexual orientation, immigration status, education, HCV coinfection, time since HAART initiation, CD4 cell count at HAART initiation, addictive behaviour, current trial participation, side effects, and adherence, when relevant). If the random variable was no longer significant, then the previously found effect was due only to differences in population structure and a given patient had the same chance of treatment outcome regardless of facility.
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Because including centres with very few subjects could result in a lack of robustness, we performed a sensitivity analysis by restricting the analysis to departments with at least five participating patients and then with at least 10 participants. All statistical analyses were performed using SAS 9.1.
Results
Characteristics of departments regarding service provision
Among the 102 departments, the median size of the HIV caseload at data collection was 
Characteristics of participants
The median age of these patients was 42 years 
Structure of departments' population
As shown in Table 1 , these different categories of participants were not uniformly For the analysis population, the mean number of participants per department was 7.2 and the median 6 (IQR: [1 -10] ). highly adherent participants was 63.3%. The heterogeneity between departments was rather large: the IQR varied from 50% to 80%, with a median adherence rate of 62%.
Adherence and treatment outcomes
However, the existence of a centre effect was rejected when we tested the department as a random variable (p = 0.275).
The overall rate of immunological failure was 22.6%, with a departments' median of 20% and an IQR of 0% to 40%. No centre effect existed here either (p = 0.215).
The overall rate of virological failure was 12.5%, with a median rate of 7.7%. Only a quarter of the departments had rates above 20%, and 44.3% had no virological failures.
Again, no centre effect was detected (p =0.098).
The mean immunovirological failure was 6.1%. Three quarters of the departments had a failure rate under 12.5%, and 61% had no participants in immunovirological failure.
The existence of a centre effect was rejected with a p-value of 0.181.
The criteria defining immunovirological treatment success, i.e. a CD4 count over 500/ml and undetectable HIV-RNA, were met by 40.2% of patients. The median department success rate was 36.3%: a quarter had rates only below 13.3%, and another quarter had rates above 50%. The random variable appeared to be significant (p=0.026) for this indicator. A centre effect thus existed, at least when tested for the entire population analysed. Nevertheless, the random term was not significant when a covariate measured on the individual level was introduced, such as the patient CD4 cell count≤200/mm
Our sensitivity analysis consisted in rerunning these models with restricting the analysis population first to the 601 patients of the 60 departments that had at least five participating patients, and secondly to the 378 patients of the 26 departments that had at least ten participating patients.
For adherence, as for the three first indicators of treatment failure, the absence of a centre effect was confirmed. Concerning immunovirological success, the random variable was still significant in the first restriction (p=0.030) and almost still significant in the second restriction to departments with at least 10 patients (p=0.053). Adjusting on covariates measured on the individual level returned as previously a non-significant random term.
Discussion
This study used data from a large random sample of hospitals providing HIV care, both representative at the national level and very diverse in terms of size, region, localisation in either metropolitan areas or medium-sized cities, activity, and specialisation. We Because of the cross-sectional design of the VESPA study, treatment failure might have been underestimated: deaths that occurred between diagnosis and data collection were not taken into account in the calculation of failure rate. In the HAART era, mortality remains much higher among patients diagnosed with advanced infection than among patients diagnosed before reaching the criteria for treatment initiation [18] . In the former group, the physician's experience may play a critical role [4,6,8,9,10].
Our study considered only hospitals caring for a substantial number (60 or more) of persons with HIV. Patients followed in smaller HIV-oriented services are not included although they might have different HIV outcomes. However, the hospitals included provided care for an estimated 90% of the HIV patient population followed in hospitals.
Random sampling ensured the representativeness of each hospital department caseload, but differential participation was related to individual patient characteristics, including lower CD4 cell counts. Participation bias might thus explain the absence of centre effects, especially if patients with poor treatment outcomes had tended to participate less in the hospitals with the poorest outcome rates. As last known CD4 cell count and viral load were available for every eligible patient, we were able to verify that this was not the case, using a mixed binary model which explained the participation of eligible patients by their health status and the treatment outcome rate of their hospital department.
Despite a low number of participants in some departments, we believe that the absence of an observed centre effect is unlikely to be due to lack of power. The assumptions of the random coefficient model we use seem appropriate here, and neither the estimates nor p values changed substantially when the analysis was restricted to the two subsamples with the hospital departments reaching either five or 10 patients with at least 6 months on HAART. show that when treatment is provided at no charge, its efficacy reach the same levels in southern countries as it does in northern countries [21] . Accessibility will require that antiretroviral treatment be provided through medical facilities in the community. Longterm networking and training of HIV care providers to improve and maintain high standard skills should be planned to ensure the equal outcomes that should accompany truly equal access to effective treatment. 
